双线并购补短板，明德生物密集推进股权收购计划

Core Insights - Mingde Biological has initiated two equity acquisitions to focus on emergency rescue and in vitro diagnostic instruments, driven by declining COVID-19 testing business and increasing competition in the in vitro diagnostic industry [1][6] Group 1: Acquisition Details - On December 31, 2025, Mingde Biological signed a framework agreement with Blue Sail Medical to acquire 100% of Wuhan Bikaier Rescue Supplies Co., Ltd. for cash [2] - Wuhan Bikaier, a leader in emergency rescue, reported a revenue of 165 million yuan and a net profit of 13.87 million yuan in 2024, with a revenue of 75.8 million yuan and a net profit of 7.52 million yuan in the first half of 2025 [2] - The acquisition aims to enhance Mingde Biological's market position in critical care by integrating emergency protection services into industrial and household scenarios [2] Group 2: Second Acquisition - On January 20, 2026, Mingde Biological announced a plan to acquire 51% of Hunan Lanyi Medical Equipment Co., Ltd. for a total price of 35.71 million yuan, making it a subsidiary [3][4] - Hunan Lanyi focuses on IVD instruments and has significant potential in the market, particularly in glycosylated hemoglobin testing [4] - The acquisition includes performance commitments, with Hunan Lanyi required to achieve an average net profit of at least 20 million yuan over three years to trigger further acquisition phases [5] Group 3: Financial Performance - Mingde Biological's revenue has faced significant declines, with 2023 and 2024 revenues at approximately 750 million yuan and 350 million yuan, representing year-on-year declines of 92.88% and 53.30% respectively [6] - The company reported a net profit of approximately 74.93 million yuan in 2023, down 9.22% year-on-year, and a net profit of about 74.52 million yuan in 2024, down 0.54% year-on-year [6] - As of September 30, 2025, the company's cash reserves were 184 million yuan, a decrease of 63% from the beginning of the period [6]